FDA Approval: ALECENSA (ALECTINIB HYDROCHLORIDE) — Type 1 - New Molecular Entity
Policy FDA-NDA208434 · Oncology
Alecensa, an oral medication, will fall under Medicare Part D for drug coverage. As it is a new molecular entity and an orphan drug, billing teams should monitor for specific coding and formulary upda